Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 1998

View Archived Issues

Company Profile: Select Therapeutics

Genelabs Technologies: Q4 and year-end 1997 highlights

Anesta: year-end 1997 highlights

Texas Biotechnology: Q4 1997 highlights

Virus Research Institute: Q4 and FY 1997 highlights

Annual Report 1996/1997: Asta Medica

First approvals for Zadaxin outside Asia

Patent coverage for Metabasis Therapeutics' adenosine kinase inhibitors

Novel antiviral agents from Lilly

Bristol-Myers Squibb developing new paclitaxel derivatives

Corvas prepares new orally active antithrombotic agents

S-8921: specific inhibitor of ileal bile acid transport for hypercholesterolemia

Profile of a motilide: Abbott's ABT-229

Takeda in negotiations with potential marketing partner for pioglitazone

Kirin Brewery will collaborate with Chugai on PB-94 development

Antioxidant and neuroprotective effects of GSNO confirmed

Yamanouchi terminates IFN marketing agreement with Schering-Plough

Nicotine inhaler launched in U.S.

Gene delivery technology offered for licensing

ICAgen issued patents on novel ion channel drug discovery technology

Naked DNA delivery technology offered for licensing

LXR and Copernicus establish cancer gene therapy collaboration

Pharmacodynamics of HMR-3647 against respiratory pathogens, enterococci and B. fragilis

New company created for development of cell therapies

Lilly glycopeptide antibiotic compared to vancomycin and teicoplanin in vitro

New compound for mucositis in development at Alizyme

HBED proposed as alternative to deferoxamine as iron chelator

FDA requests additional information for EchoGen NDA review

NIH offers new technology for licensing